Skip to content
OpenCapital
Get started

Henry Schein HSIC Deferred compensation plan assets

Deferred compensation plan assets at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$3.4B+6.3%
Gross profit$1.1B+7.0%
Operating income$182.0M+4.0%
Net income$107.0M-2.7%
EPS (diluted)$0.92+4.5%

Balance sheet

See full
Cash & equivalents$138.0M+8.7%
Total debt$3.7B+17.2%
Total equity$3.3B-1.3%
Total assets$11.3B+7.9%

Cash flow

See full
Operating cash flow-$97.0M-362%
CapEx$25.0M-19.4%
Free cash flow-$122.0M-2,133%

Valuation

See full
Market cap$9.1B-0.6%
Enterprise value$12.69B+4.2%
P/E23.1×+0.5×
P/S0.7×0.0×

Profitability

See full
Gross margin31.2%-0.4pp
Operating margin4.9%-0.2pp
Net margin3%-0.3pp
FCF margin3.3%-1.0pp

Returns & leverage

See full
Return on equity12%+0.2pp
Debt / equity1.1×+0.2×
Current ratio1.4×0.0×

Where this comes from

Reported directly by Henry Schein in its filing.

Tagged under the XBRL concept us-gaap:DeferredCompensationPlanAssets.

The official record: Henry Schein’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Henry Schein's deferred compensation plan assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Henry Schein's deferred compensation plan assets?
Henry Schein (HSIC) reported deferred compensation plan assets of $11M in Q4 2025.
What is the long-term trend for Henry Schein's deferred compensation plan assets?
Over 3 years (2022 to 2025), Henry Schein's deferred compensation plan assets has grown at a 11.2% compound annual growth rate (CAGR), from $8M to $11M.